Reframing MASLD: A Hepatic Condition With Systemic Clinical Impact

Key Takeaways for GI Nurses

• MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD) should be viewed as a multisystem disease, not an isolated hepatic finding—nurses should anticipate and screen for cardiovascular, renal, and metabolic comorbidities in these patients.
• Patients presenting for endoscopic procedures with incidental steatosis, elevated liver enzymes, or known MASLD may carry higher perioperative risk related to cardiometabolic disease, warranting more thorough pre-procedure risk assessment.
• Patient education around MASLD should extend beyond liver-focused messaging to address weight management, glycemic control, and cardiovascular risk reduction as part of a holistic care plan.
• Nurses play a key role in care coordination, helping bridge hepatology, endocrinology, cardiology, and primary care for patients whose liver disease is really a marker of broader systemic dysfunction.

Clinical Relevance

This publication reinforces a shift already underway in hepatology: MASLD is no longer conceptualized as a liver-only condition but as a hepatic manifestation of systemic metabolic dysfunction closely tied to obesity, insulin resistance, type 2 diabetes, dyslipidemia, and cardiovascular disease. For GI and endoscopy nurses, this reframing matters practically. Many patients undergoing routine endoscopy, colonoscopy, or hepatology-referred procedures carry an unrecognized or underappreciated burden of metabolic disease that intersects directly with anesthesia risk, wound healing, bleeding risk, and post-procedure recovery. Recognizing MASLD as a systemic condition encourages nurses to look beyond liver function tests and imaging findings toward a more complete cardiometabolic picture during intake assessments.

From an operational standpoint, this broader framing supports more robust pre-procedure screening protocols. Nurses conducting pre-endoscopy assessments may need to pay closer attention to blood pressure, glycemic status, BMI, and cardiovascular history in patients with known or suspected MASLD, since these comorbidities can influence sedation planning, monitoring intensity, and post-procedure discharge criteria. Units may also consider incorporating standardized metabolic risk screening tools into intake documentation for patients with steatotic liver disease, ensuring that findings are communicated clearly to the endoscopist and anesthesia team before the procedure begins.

For professional development, this research underscores the importance of ongoing education on MASLD terminology, pathophysiology, and its systemic implications. As the nomenclature and clinical understanding continue to evolve—from NAFLD to MASLD and its associated subtypes—nurses are often the first point of contact for patient questions and education. Staying current allows nursing staff to deliver accurate, consistent counseling on lifestyle modification, comorbidity management, and the rationale for multidisciplinary referrals, strengthening the nurse's role as a patient advocate and educator within the broader care team.

Bottom Line

GI nurses should treat MASLD as a signal of systemic metabolic risk rather than an isolated liver finding, integrating cardiometabolic screening, patient education, and care coordination into standard practice for these patients across the endoscopy and GI care continuum.